Cavan Appoints Dr. Manju Sharma MD and Doctor of Naturopathy to Advisory Board

CAVAN VENTURES INC. (TSX VENTURE:CVN) ("Cavan" or the "Company") is pleased to
provide a corporate update in regards to the continuing exploration of the
potential of the Medical Marijuana and Hemp/Cannabinoid industry. 


Cavan Ventures Inc. previously announced (see news release dated 2014-03-25) the
diversification of its growth plan into the Medical Marijuana and Hemp industry.
To accelerate this process, Dr. Manju Sharma has joined the Company as its
newest member to the advisory board.


Dr. Manju Sharma is a medical doctor, working currently as a scientist at
Vancouver Prostate Centre, Vancouver General Hospital for the last 5 years.
Prior to this she worked in the department of Pathology and Lab Medicine, VGH
for 10 years on various projects including molecular diagnosis of tuberculosis,
multi-drug resistant tuberculosis, human solid tumors, kidney disorders,
medicinal herbal plants like Echinacea which is widely used all over Europe and
North America for the treatment of cough and cold: active principles and their
mode of action on various human viral and bacterial diseases. She has published
over 70 papers in medical journals and has made several presentations in the
field of Medicine.


Though trained in Allopathic or Western medicine, she has been always intrigued
by the power of alternative /herbal medicine for e.g., Cannabis plant. The
therapeutic properties of the hemp plant, Cannabis sativa, have been known for
many years, but the recreational use of its psychoactive effects has restricted
its possible pharmaceutical application. To date, cannabinoids have been
successfully used in the treatment of nausea and vomiting, two common side
effects that accompany chemotherapy in cancer patients. Most non-THC plant
cannabinoids e.g. cannabidiol and cannabigerol, seem to be devoid of
psychotropic properties. Her paper on, "In vitro anticancer activity of
plant-derived cannabidiol on prostate cancer cell lines", has been accepted in
the Journal of Pharmacology and Pharmacy and will go on-line in July, 2014. Her
overall findings support the concept that cannabidiol, which lacks psychotropic
activity, may possess anti-inflammatory and anticancer property. Cannabidiol and
other non-habit forming cannabinoids could be used as novel therapeutic agents
for the treatment of prostate cancer. Her case studies confirmed cannabinoid
efficacy in reducing muscle spasticity in multiple sclerosis (Hornby and Sharma
2010), pain levels over a 12 month period (Hornby and Sharma 2009) and Cannabis
responsive head injury induced multiple disabilities (Sharma. 2012).


She is also working as a Natural Health consultant and analyzing cannabinoids
(THC, CBD and CBN) by Gas Chromatography for the members of Green Cross Society
of BC. This helps the members to choose the right cannabis strain for smoking
and thereby help them to regulate their cannabis dose. Cannabis capsules are
also available for the patients who want to take this medicine orally. Cannabis
with high CBD and low THC are heat treated, chemically characterized using
chromatography and Cannacaps (capsules) are available for oral use. At Green
Cross society of BC, Cannacaps with high CBD and low THC are made available to
the patients of breast cancer, prostate cancer and other medical problems like
pain, inflammation, epilepsy, spasticity and eating disorders.


To view references published in the last 8 years, visit the following link:
http://media3.marketwire.com/docs/CVN%20References.pdf. 


Peter P. Swistak, President/CEO of Cavan Ventures Inc., states, "The depth and
scope of Dr. Sharma's knowledge is unparalleled and Cavan is very fortunate to
have access to this knowledge as we believe Dr. Sharma is the best in her field
with an extensive bio and published research. Dr. Sharma will add tremendous
value, credibility and unique knowledge to Cavan in its analysis of the Medical
Marijuana and Hemp/Cannabinoid industry, and potential opportunities in that
industry. We are excited to have Dr. Sharma available to us while we conduct
due-diligence in the Cannabinoid/Medicinal Marijuana space."


At this time, no transactions are in place, nor is there any assurance that a
new project will be concluded in the future.


For more information visit the website at www.cavanventuresinc.com.

ON BEHALF OF THE BOARD

Peter P. Swistak, President

Forward-Looking Statement: Certain statements in this release are
forward-looking statements, which reflect the expectations of management
regarding the Company's plans with respect to its existing graphite interests,
future financings, and the analysis and investigation of the medical marijuana
sphere. Forward-looking statements consist of statements that are not purely
historical, including any statements regarding beliefs, plans, expectations or
intentions regarding the future and statements concerning the anticipated
drilling programs, future financings, and the Company proceeding with any
transactions in the medical marijuana sphere. Such statements are subject to
risks and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the statements. No
assurance can be given that any of the events anticipated by the forward-looking
statements will occur or, if they do occur, what benefits the Company will
obtain from them. In particular, the Company cautions that any financings or
potential transactions cannot be predicted with certainty, and there can be no
assurance at this time that all required or desirable approvals and consents to
affect future financings or proposed transactions will be achieved at all. These
forward-looking statements reflect management's current views and are based on
certain expectations and assumptions which may prove to be incorrect. A number
of risks and uncertainties could cause our actual results to differ materially
from those expressed or implied by the forward-looking statements, including
factors beyond the Company's control. These forward-looking statements are made
as of the date of this news release.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cavan Ventures Inc.
1-604-683-3995 or Toll Free: 1-888-945-4770
www.cavanventuresinc.com